IP Library Granted Patent US 9,714,426
Granted Patent B2
US 9,714,426 · App. 14/658,176 · Granted Jul 25, 2017

Bacteria mediated gene silencing

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,714,426
App. No.
14/658,176
Granted
Jul 25, 2017
Kind
B2
Abstract

Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium or BTP. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating viral diseases and disorders. The bacterium or BTP includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells.

Claims (9)

1. An invasive bacterium comprising a prokaryotic vector, said vector comprising one or more DNA molecules encoding one or more siRNAs, at least one Inv gene and at least one HlyA gene, wherein the siRNAs are targeted to a viral gene, wherein at least one of the siRNAs is SEQ ID NOs:384 and 385.

2. A prokaryotic vector comprising at least one DNA molecule encoding one or more siRNAs, at least one Inv gene, at least one HlyA gene, and at least one prokaryotic promoter, wherein the siRNAs are targeted to a viral gene, and wherein at least one of the siRNAs is SEQ ID NOs:384 and 385.

3. The invasive bacterium of claim 1 , wherein said invasive bacterium is a non-pathogenic or non-virulent bacterium.

4. The invasive bacterium of claim 1 , wherein said invasive bacterium is a therapeutic bacterium.

5. A composition comprising the invasive bacterium of claim 1 and a pharmaceutically acceptable carrier.

6. A eukaryotic host cell comprising the invasive bacterium of claim 1 , and a pharmaceutically acceptable carrier.

7. The invasive bacterium of claim 1 , wherein said invasive bacterium is attenuated.

8. The prokaryotic vector of claim 2 , wherein said prokaryotic promoter is a P tac promoter.

9. The prokaryotic vector of claim 2 , further comprising a rrnC terminator.

Assignments (1)
SECURITY INTEREST Recorded Nov 23, 2021
From: ADHERA THERAPEUTICS, INC.
To: CAVALRY FUND I LP
Reel/Frame 058312/0195 →